Aemetis, Inc. Reports Third Quarter 2020 Financial Results
Aemetis, Inc. (NASDAQ:AMTX) reported its financial results for Q3 2020, showing revenues of $40.9 million, down from $57.4 million in Q3 2019. The net loss was $12.2 million, compared to $7.2 million the previous year. Ethanol and high-grade alcohol sales increased by 11%, while biodiesel sales surged 216% compared to Q2 2020. The company achieved milestones in its dairy biogas project and launched Aemetis Health Products to meet sanitizer demand. Total revenues for the first nine months of 2020 were $128.2 million, an 14.6% decline from 2019.
- Ethanol and high-grade alcohol sales increased by 11% from Q2 2020.
- Biodiesel sales rose 216% compared to Q2 2020.
- Launch of Aemetis Health Products to meet sanitizer demand.
- Revenues decreased from $57.4 million in Q3 2019 to $40.9 million in Q3 2020.
- Net loss increased from $7.2 million in Q3 2019 to $12.2 million in Q3 2020.
- Adjusted EBITDA was negative $2.5 million for Q3 2020.
CUPERTINO, CA / ACCESSWIRE / November 12, 2020 / Aemetis, Inc. (NASDAQ:AMTX), an advanced renewable fuels and biochemicals company innovating the reduction of carbon intensity, today announced its financial results for the three and nine months ended September 30, 2020.
Aemetis' third quarter of 2020 included significant announcements and financial achievements:
- Ethanol and high-grade alcohol gallons sold increased
11% to 15.2 million gallons compared to the second quarter of 2020 - Biodiesel metric tons sold increased
216% compared to the second quarter of 2020 - Revenues were
$40.9 million during the third quarter - Net Loss was
$12.2 million ($0.59 per share)
"In the third quarter, the Aemetis Biogas team achieved several significant milestones by completing the first phase of our dairy digester cluster project, including the commissioning of a four mile Aemetis-owned pipeline and two dairy digesters that are now producing below zero carbon intensity biogas," said Eric McAfee, Chairman & CEO of Aemetis, Inc. "The biogas team is working to rapidly build 16 additional dairy digesters under 25 year contracts, a centralized gas clean up unit, and about 26 more miles of pipeline in the Aemetis dairy digester cluster, which is expected to be fully completed within about 18 months. In 2021, Aemetis will be able to inject dairy renewable natural gas into the common carrier pipeline and utilize an onsite renewable compressed natural gas fueling station," McAfee added.
Demand for high grade alcohol for sanitizer production and shipments of bulk alcohol to sanitizer alcohol customers launched strongly in the second quarter of 2020 at the onset of the COVID-19 pandemic, but then softened during the third quarter of 2020 due to inferior product from overseas and customer resulting demand for United States Pharmacopeia grade alcohol. Responding to this continued market demand for high-quality sanitizer and health products, Aemetis expanded its sustainable advantage as the largest West Coast producer of high grade alcohol for sanitizer and health products by launching Aemetis Health Products. This new subsidiary extended the business into the production and distribution of branded and private label blended liquid and gel sanitizer and other health safety products.
"After obtaining the Food and Drug Administration National Drug Code for sanitizer products, Aemetis Health Products began production during the third quarter to expand product offerings into key markets for hand sanitizers, personal care and cleaning products. Sales of the new sanitizer products are planned to be supported by production of United States Pharmacopeia medical grade alcohol beginning in the first half of 2021," said McAfee.
To reduce the carbon intensity of our products, Aemetis commenced project development for two significant ethanol plant energy upgrade projects, including a large solar microgrid that is expected to produce approximately 1.5MW of renewable energy at the Keyes plant, and a mechanical vapor recompression (MVR) upgrade that, when combined with the solar project, is engineered to reduce the plant's natural gas steam usage by approximately
This month, Aemetis participated in a
Today, Aemetis will host an earnings review call at 11:00 a.m. Pacific time (PT).
Live Participant Dial In (Toll Free): +1-844-407-9500
Live Participant Dial In (International): +1-862-298-0850
Webcast URL: https://www.webcaster4.com/Webcast/Page/2211/38376
For details on the call, please visit http://www.aemetis.com/investors/conference-calls/
Financial Results for the Three Months Ended September 30, 2020
Revenues were
Gross profit for the third quarter of 2020 was
Selling, general and administrative expenses remained flat at
Operating loss increased to
Interest expense during the third quarter of 2020 was
Net loss was
Adjusted EBITDA was negative
Cash at the end of the third quarter of 2020 was
Financial Results for the Nine Months Ended September 30, 2020
Revenues were
Selling, general and administrative expenses were
Operating income was
Interest expense was
Net loss for the first three quarters of 2020 was
Adjusted EBITDA was
About Aemetis
Headquartered in Cupertino, California, Aemetis is an advanced, renewable fuels and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products by the conversion of ethanol and biodiesel plants into advanced biorefineries. Founded in 2006, Aemetis owns and operates a 65 million gallon per year ethanol production facility in California's Central Valley near Modesto. Aemetis also owns and operates a 50 million gallon per year renewable chemical and advanced fuel production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India and Europe. Aemetis is building a biogas anaerobic digester network and pipeline to convert dairy animal waste gas to Renewable Natural Gas (RNG) and is developing a plant to convert waste orchard wood into high grade cellulosic alcohol. Aemetis holds a portfolio of patents and related technology licenses for the production of renewable fuels and biochemicals. For additional information about Aemetis, please visit www.aemetis.com.
NON-GAAP FINANCIAL INFORMATION
We have provided non-GAAP measures as a supplement to financial results based on GAAP. A reconciliation of the non-GAAP measures to the most directly comparable GAAP measures is included in the accompanying supplemental data. Adjusted EBITDA is defined as net income/(loss) plus (to the extent deducted in calculating such net income) interest expense, loss on extinguishment, income tax expense, intangible and other amortization expense, accretion expense, depreciation expense, loss contingency on litigation and share-based compensation expense.
Adjusted EBITDA is not calculated in accordance with GAAP and should not be considered as an alternative to net income/(loss), operating income or any other performance measures derived in accordance with GAAP or to cash flows from operating, investing or financing activities as an indicator of cash flows or as a measure of liquidity. Adjusted EBITDA is presented solely as a supplemental disclosure because management believes that it is a useful performance measure that is widely used within the industry in which we operate. In addition, management uses Adjusted EBITDA for reviewing financial results and for budgeting and planning purposes. EBITDA measures are not calculated in the same manner by all companies and, accordingly, may not be an appropriate measure for comparison between companies.
Safe Harbor Statement
This news release contains forward-looking statements, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, expectations for growth in India and development of our cellulosic ethanol business in North America. Words or phrases such as "anticipates," "may," "will," "should," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "showing signs," "targets," "view," "will likely result," "will continue" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, demand for high grade alcohol and related products, including hand sanitizers, and other risks detailed in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2019, our Quarterly Report on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020 and in our subsequent filings with the SEC. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.
External Investor Relations Contact:
Kirin Smith
PCG Advisory Group
(646) 863-6519
ksmith@pcgadvisory.com
Investor Relations/
Media Contact:
Todd Waltz
(408) 213-0940
investors@aemetis.com
(Tables follow)
AEMETIS, INC.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(unaudited, in thousands except per share data)
| Three months ended | Nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
Revenues | $ | 40,923 | $ | 57,389 | $ | 128,227 | $ | 149,896 | ||||||||
Cost of goods sold | 40,152 | 53,407 | 113,830 | 142,992 | ||||||||||||
Gross profit | 771 | 3,982 | 14,397 | 6,904 | ||||||||||||
Research and development expense | 37 | 37 | 175 | 160 | ||||||||||||
Selling, general and admin. expense | 4,563 | 4,529 | 12,548 | 12,715 | ||||||||||||
Operating income (loss) | (3,829 | ) | (584 | ) | 1,674 | (5,971 | ) | |||||||||
Interest expense | ||||||||||||||||
Interest rate expense | 5,796 | 5,396 | 16,956 | 15,572 | ||||||||||||
Amortization expense | 674 | 946 | 2,578 | 3,565 | ||||||||||||
Accretion of Series A preferred units | 1,765 | 589 | 4,087 | 1,509 | ||||||||||||
Loss contingency on litigation | -- | -- | -- | 6,200 | ||||||||||||
Other (income) expense | 153 | (289 | ) | 393 | (1,001 | ) | ||||||||||
Loss before income taxes | (12,217 | ) | (7,226 | ) | (22,340 | ) | (31,816 | ) | ||||||||
Income tax expense (benefit) | -- | -- | (263 | ) | 7 | |||||||||||
Net loss | $ | (12,217 | ) | $ | (7,226 | ) | $ | (22,077 | ) | $ | (31,823 | ) | ||||
Non-controlling interest | -- | (900 | ) | -- | (2,832 | ) | ||||||||||
Net loss attributable to Aemetis, Inc. | $ | (12,217 | ) | $ | (6,326 | ) | $ | (22,077 | ) | $ | (28,991 | ) | ||||
Net loss per common share | ||||||||||||||||
Basic | $ | (0.59 | ) | $ | (0.31 | ) | $ | (1.06 | ) | $ | (1.42 | ) | ||||
Diluted | $ | (0.59 | ) | $ | (0.31 | ) | $ | (1.06 | ) | $ | (1.42 | ) | ||||
Weighted average shares outstanding | ||||||||||||||||
Basic | 20,861 | 20,554 | 20,732 | 20,433 | ||||||||||||
Diluted | 20,861 | 20,554 | 20,732 | 20,433 | ||||||||||||
AEMETIS, INC.
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands)
September 30, 2020 (Unaudited) | December 31, 2019 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 79 | $ | 656 | ||||
Accounts receivable, net | 3,243 | 2,036 | ||||||
Inventories | 4,816 | 6,518 | ||||||
Prepaid and other current assets | 5,409 | 3,366 | ||||||
Total current assets | 13,547 | 12,576 | ||||||
Property, plant and equipment, net | 103,050 | 84,226 | ||||||
Right-of-use and other assets | 5,573 | 3,094 | ||||||
Total assets | $ | 122,170 | $ | 99,896 | ||||
Liabilities and stockholders' deficit | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 15,023 | $ | 15,968 | ||||
Current portion of long-term debt | 41,979 | 5,792 | ||||||
Short-term borrowings | 17,357 | 16,948 | ||||||
Mandatorily redeemable Series B stock | 3,226 | 3,149 | ||||||
Accrued property taxes and other current liabilities | 18,240 | 15,962 | ||||||
Total current liabilities | 95,825 | 57,819 | ||||||
Total long term liabilities | 201,908 | 196,449 | ||||||
Stockholders' deficit: | ||||||||
Series B convertible preferred stock | 1 | 1 | ||||||
Common stock | 21 | 21 | ||||||
Additional paid-in capital | 88,119 | 86,852 | ||||||
Accumulated deficit | (259,498 | ) | (237,421 | ) | ||||
Accumulated other comprehensive loss | (4,206 | ) | (3,825 | ) | ||||
Total stockholders' deficit | (175,563 | ) | (154,372 | ) | ||||
Total liabilities and stockholders' deficit | $ | 122,170 | $ | 99,896 | ||||
RECONCILIATION OF ADJUSTED EBITDA TO NET LOSS
(unaudited, in thousands)
| Three Months Ended | Nine Months Ended | ||||||||||||||||
| September 30, | September 30, | ||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||||
Net loss attributable to Aemetis, Inc. | $ | (12,217 | ) | $ | (6,326 | ) | $ | (22,077 | ) | $ | (28,991 | ) | |||||
Adjustments: | |||||||||||||||||
Interest expense | 6,470 | 5,545 | 19,534 | 16,620 | |||||||||||||
Loss contingency on litigation | -- | -- | -- | 6,200 | |||||||||||||
Depreciation expense | 1,253 | 1,103 | 3,515 | 3,337 | |||||||||||||
Accretion of Series A preferred units | 1,765 | 589 | 4,087 | 1,509 | |||||||||||||
Share-based compensation | 191 | 144 | 826 | 630 | |||||||||||||
Intangibles and other amortization expense | 12 | 12 | 36 | 36 | |||||||||||||
Income tax expense (benefit) | -- | -- | (263 | ) | 7 | ||||||||||||
Total adjustments | 9,691 | 7,393 | 27,735 | 28,339 | |||||||||||||
Adjusted EBITDA | $ | (2,526 | ) | $ | 1,067 | ||||||||||||
FAQ
What were Aemetis' revenues for Q3 2020?
How much did Aemetis lose in Q3 2020?
What drove Aemetis' revenue decline in Q3 2020?
What is the outlook for Aemetis in 2021?
